Grifols buys 40% from Kiro Robostics for €12.8M, taking control of 90% of the company.

, , ,
Integral service around a transaction
BY : Diego GutiérrezJuly Wed, 2017
Kiro Robotics, which is now called Kiro Grifols, develops machines and equipment to automate or control key points of hospital processes, especially hospital pharmacy services, including Kiro Oncology, which automatically prepares intravenous medication for chemotherapy treatments in hospital pharmacies, minimising margins of error in the preparation of medication and the risk to healthcare professionals.
About Kiro Robotics

Kiro Robotics is a spin-off, i.e. a company that emerged from the strategic unit dedicated to the health area (Mondragon Health) of the Mondragon Corporation. Created in 2011, Kiro Robotics develops machines and equipment that automate or control key points of hospital processes, especially hospital pharmacy services.

Grifols purchased the company's 40% in 2014 and began direct commercialisation of Kiro Oncology in January 2016.

Grifols' entry into the company, with its healthcare experience and liquidity resources, favoured the development of its products and the possibility of international growth. Kiro currently sells its products to some of the most important hospitals in the United States, including Ann & Robert H. Lurie Children's Hospital in Chicago (a leading children's hospital) and Smilow Cancer Hospital in Yale-New Haven (one of only 45 centres with National Cancer Institute designation).

Grifols buys 40% from Kiro Robotics

With this purchase for 12.8 million euros, Grifols strengthens its hospital division by reinforcing its commitment to innovation, project continuity and internationalisation.

Grifols, which is listed on the Ibex, is one of the three leading companies in the world in the production of plasma-derived medicines and a pioneering group in research and development of therapeutic alternatives. Last year, Grifols had a turnover of 3,935 million euros.

This is not the first time that Grifols has made acquisitions in the Basque Country. In March last year, Grifols acquired 60 % of the capital of the Basque biotech company Progenika Biopharma for a total of 37 million euros.

Grifols, active in investments

 Grifols has earmarked around 400 M to enter the capital of small leading companies, apart from the 5,790 million allocated to the large acquisitions of Talecris, and the diagnostic divisions of Novartis and Hologic, linked to the growth of its traditional business.

The latest investment was the purchase of GigaGen, for 35 million dollars (30.8 million euros). This company is dedicated to the discovery of new biological therapies based on the use of antibodies from immune system cells.

The acquisitions of stakes in these companies revolve around several common axes: strengthening the capacity and safety of plasma collection, providing technological innovations for the business, and investing in leading Spanish technology companies. The Catalan company makes these purchases through Grifols Innovation and New Technologies Limited, where all external R&D investments are grouped together.

Other posts that may interest you

GED Venture Capital has invested in Vitro, a Spanish in vitro diagnostics and laboratory software company.

If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?